Objective: To investigate whether there is any association between exposure to atazanavir (ATV), either when boosted or unboosted by ritonavir, and myocardial infarction (MI) or stroke within the D:A:D: Study.
Introduction
HIV-positive patients are believed to experience several non-HIV-related diseases at a higher frequency than the general population. Several hypotheses have been proposed for this [1] . Firstly, HIV-positive individuals may experience premature ageing due to the chronic inflammation and immune activation that results from HIV infection [2] . Secondly, drug-related toxicities have been documented for most antiretroviral drugs; those related to lipid and glucose metabolism may, in turn, result in an increased risk of cardio and cerebrovascular disease (CCVD) [3] . Finally, lifestyle or behavioural factors may place those living with HIV at higher underlying risk of these diseases.
The D:A:D Study is an ongoing multicentre cohort study that was designed to ascertain possible links between CVD and antiretroviral drug usage, the main end-point being myocardial infarction (MI). Previous analyses of the D:A:D Study have shown that the duration of exposure to antiretroviral drugs and, in particular, to protease inhibitor-containing, but not non-nucleoside-containing combination antiretroviral therapy (cART), was associated with increased risk of MI [4] . Subsequent analyses have demonstrated that greater exposure to lopinavir or indinavir was associated with an increased risk of MI, whereas such an association was not seen for other protease inhibitors, particularly saquinavir and nelfinavir [5] . Due to the limited follow-up at the time among persons exposed to atazanavir (ATV), the association between exposure to this drug and MI was not previously investigated. However, sufficient person-years of followup (PYFU) have now accrued among those exposed to ATV to permit an investigation of the association between ATV and the risk of CCVD (MI or stroke).
Methods
The D:A:D Study is an international collaboration of 11 cohorts, which captures information on more than 49 000 HIV-positive patients, regardless of prior antiretroviral use, from Europe, Australia, and the USA. Details of the study methods have been reported [6] . Information is collected annually on demographics, AIDS events and deaths, known risk factors for CCVD, laboratory markers for monitoring HIV and CCVD, antiretroviral use and treatments that modify CCVD risk. All information is transformed into a standardized format and merged centrally. The analyses reported in this study are based on data collected up to 1 February 2011.
All incident cases of MI are reported to the study coordinating office for validation and coding. Reported MIs are classified as: definite, possible, or unclassifiable, and are further distinguished as nonfatal (survival to at least 28 days after onset) or fatal (all other events). Reported strokes are classified as: definite/probable, stroke-like event, or not stroke (only definite/probable strokes were included in the present analysis), and are further classified by the type of lesion as infarction, haemorrhage or unknown. The classification of MI and stroke was conducted according to criteria applied in the WHO MONICA study [7] .
Poisson regression was used to investigate the association between cumulative exposure to ATV and MI risk after adjusting for known demographic and clinical confounders for MI risk (sex, age, ethnicity, mode of HIV acquisition, participating clinical cohort, BMI, family history of coronary heart disease, smoking status, history of cardiovascular disease and calendar year) as well as cumulative exposure to each specific antiretroviral and recent exposure to each nucleoside reverse transcriptase inhibitor. Analyses of the stroke outcome were performed in a similar way, with adjustment for known stroke risk factors (sex, age, BMI, smoking status, history of cardiovascular disease, hypertension and calendar year) as well as cumulative and recent use of antiretroviral drugs, as described for the MI outcome. For each analysis, follow-up started on the date of enrolment in the D:A:D Study and ended at the earliest of a new MI/stroke event, death, 6 months after last clinic visit or 1 February 2011. Note that follow-up times for the two analyses could differ slightly as patient follow-up was not censored on the date of an MI for analyses of the stroke outcome, and vice versa. Thus, participants were followed for a total of 301 907 PYFU for analyses of MI, and 303 118 PYFU for analyses of stroke. The characteristics of the two patient sub-populations are, however, very similar, and therefore we present information on the MI sub-population below.
Analyses for the MI outcome were repeated after considering only definite MIs. Finally, as ATV has predominantly been used since 2005, we repeated our previous analyses of the associations between MI risk and specific protease inhibitor drugs after restricting the analysis to the period over which ATV was used (2005 ATV was used ( -2011 .
Results
A total of 844 new MIs and 523 new strokes were diagnosed in the 49 734 D:A:D participants [incidence of Overall, 37 005 (12.3% of total) PYFU were contributed by patients who had ever been exposed to ATV, 31 502 (10.4%) by patients who had ever been exposed to ATV with boosted ritonavir (RTV) and 9611 (3.2%) by patients who had ever been exposed to ATV without RTV (patients may have received ATV in both its boosted and unboosted form, hence this sums to more than 37 005 PYFU). The characteristics of patients in the study, stratified by whether they were currently receiving an ATV-based regimen, other antiretroviral regimen or were not on antiretroviral therapy, are shown in Table 1 . There were no major differences between the characteristics of patients receiving ATV or other regimens. As expected, ATV usage was more common in more recent calendar periods, with 71.9% of follow-up time on ATVoccurring from 2007 to 2011, compared to 41.8% of follow-up time on non-ATV cART regimens. As a result, information on cardiovascular risk (Framingham score) was relatively more complete for those on ATV.
The incidence of MI was 0.28 (95% CI 0.26-0.30)/100 PYFU in those with no exposure to ATV and 0.20 (95% CI 0.12-0.32)/100 PYFU in those with more than 3 years ATV exposure ( The incidence of stroke was 0.17 (95% CI 0.16-0.19)/ 100 PYFU in those with no exposure to ATV and 0.17 (95% CI 0.10-0.27)/100 PYFU in those with more than 3 years ATV exposure ( 
Discussion
In this analysis from the D:A:D Study, we have demonstrated that a longer duration of ATV usage as part of a cART regimen is not associated with an increased risk of CVD in HIV-positive individuals. As a consequence, we confirm that previously reported associations concerning lopinavir and indinavir are unlikely to reflect a class-wide association, as already suggested by our finding relating to nelfinavir and saquinavir [5] .
We explored several possible explanations for this lack of association. Firstly, we evaluated whether potential confounders might have masked a genuine association. Our multivariable analyses included adjustment for factors known to influence a clinician's choice of cART, many of which are also known CCVD risk factors; adjustment did not, however, modify the findings. We also evaluated whether the documented effect of ATV on serum bilirubin levels could explain the lack of association, based on the inverse association between bilirubin level and risk of CCVD in HIV-negative persons [8] . We found no evidence that these findings were altered by adjustment for the latest bilirubin level; of note, only limited data were available for this analysis, due to the lack of bilirubin collection in several cohort databases. It could also be argued that our findings might be explained by differences in the population of patients receiving ATV as compared to those receiving other protease inhibitors, as ATV has only been used in more recent years and patient characteristics (e.g. smoking 410 AIDS 2013, Vol 27 No 3 status) and lipid monitoring have also changed over time in the HIV-positive population [9, 10] . We thus restricted the analyses to more recent years and re-evaluated the association between CCVD and exposure to the different protease inhibitors; our analyses reached similar conclusions, confirming the main analyses (data not shown).
There are several limitations of this study. Most importantly, the observational nature of the D:A:D Study means that our findings cannot be assumed to reflect casual associations and must be interpreted cautiously because of the potential for unmeasured confounding. Furthermore, the limited availability of ATV in the clinic means that our findings may be strengthened by the inclusion of individuals exposed to ATV for longer periods of time in the coming years.
In conclusion, data from the D:A:D Study argue against an association between exposure to ATV, either boosted or unboosted with ritonavir, and the risk of CCVD, which confirms that such risk is not a class-wide phenomenon, but rather restricted to particular individual HIV protease inhibitors. Finally, we should note that the rate of MI and stroke remains relatively low in more recent years -thus any findings on possible correlations between antiretroviral drugs must be interpreted in the context of the tremendous benefits of cART for the HIVpositive population. 
